Min Jeong Kim

Min Jeong Kim

Auto-generated profile, based on publicly available information

Min Jeong Kim

Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MKMin Jeong Kim
Min Jeong Kim
HKHyo Jung Kim
Hyo Jung Kim
DKDanbee Kang
Danbee Kang
HAHee Kyung Ahn
Hee Kyung Ahn
SSSoo-Yong Shin
Soo-Yong Shin
Yeon Hee 박연희 ParkYeon Hee 박연희 Park
Yeon Hee 박연희 Park
Background: In recent decades, real-world evidence (RWE) in oncology has rapidly gained traction for its potential to answer clinical questions that cannot be directly addressed by randomized clinical trials. Integrating real-world data (RWD) into clinical research promises to contribute to more sustainable research designs, including extension, augmentation, enrichment, and pragmatic designs. Nevertheless, clinical research using RWD is still limited because of concerns regarding the shortage of best practices for extracting, harmonizing, and analyzing RWD. In particular, pragmatic screening methods to determine whether the content of a data source is sufficient to answer the research questions before conducting the research with RWD have not yet been established. Objective: We examined the PAR (Preliminary Attainability Assessment of Real-World Data) framework and assessed its utility in breast cancer brain metastasis (BCBM), which has an unmet medical need for data attainability screening at the preliminary step of observational studies that use RWD. Methods: The PAR framework was proposed to assess data attainability from a particular data source during the early research process. The PAR framework has four sequential stages, starting with clinical question clarification: (1) operational definition of variables, (2) data matching (structural/semantic), (3) data screening and extraction, and (4) data attainability diagramming. We identified 5 clinical questions to be used for PAR framework evaluation through interviews and validated them with a survey of breast cancer experts. We used the Samsung Medical Center Breast Cancer Registry, a hospital-based real-time registry implemented in March 2021, leveraging the institution’s anonymized and deidentified clinical data warehouse platform. The number of breast cancer patients in the registry was 45,129; it covered the period from June 1995 to December 2021. The registry consists of 24 base data marts that represent disease-specific breast cancer characteristics and care pathways. The outcomes included screening results of the clinical questions via the PAR framework and a procedural diagram of data attainability for each research question. Results: Data attainability was tested for study feasibility according to the PAR framework with 5 clinical questions for BCBM. We obtained data sets that were sufficient to conduct studies with 4 of 5 clinical questions. The research questions stratified into 3 types when we developed data fields for clearly defined research variables. In the first, only 1 question could be answered using direct data variables. In the second, the other 3 questions required surrogate definitions that combined data variables. In the third, the question turned out to be not feasible for conducting further analysis. Conclusions: The adoption of the PAR framework was associated with more efficient preliminary clinical research using RWD from BCBM. Furthermore, this framework helped accelerate RWE generation through clinical research by enhancing transparency and reproducibility and lowering the entry barrier for clinical researchers.

11 February 2026 in JMIR Cancer
Verified
Journal Article
Open access
BJBokyung Jo
Bokyung Jo
SKSUJIN KIM
SUJIN KIM
MKMin Jeong Kim
Min Jeong Kim
NKNayeon Kim
Nayeon Kim
ALAyoung Lee
Ayoung Lee
JCJuhee Cho
Juhee Cho
Background: A peripherally inserted central catheter (PICC) for vesicant or long-term chemotherapy is recommended for safe and sustainable drug delivery. However, maintaining its benefits requires regular and careful self-management. Although medical staff provide education and telephone consultation, proactive support accessible at any time or location remains limited. Therefore, we developed a rule-based chatbot to support PICC self-management. Objective: This study aimed to evaluate the feasibility of a chatbot designed to support PICC self-management by examining chatbot use rate, usability, and user experience. Methods: A mixed methods study was conducted from September to December 2022, adhering to the GRAMMS (Good Reporting of a Mixed Methods Study) guideline. Patients with cancer scheduled for PICC insertion and their caregivers were recruited, as PICC care is commonly performed by patients or cohabiting caregivers. All participants provided written informed consent. The chatbot was designed to provide structured responses based on prespecified dialog trees and to recognize users’ intent using natural language processing. It was delivered through KakaoTalk and accessed on participants’ personal mobile phones without requiring a separate app installation. Participants received face-to-face training at enrollment and were asked to voluntarily use the chatbot for 1 month. Baseline and postintervention surveys assessing usability were administered using paper-based questionnaires. Usage logs were collected from a secure researcher dashboard and analyzed for inquiry topics, free-text inputs, and fallback situations. Semistructured interviews were conducted approximately 1 month after the intervention during outpatient visits, with invitations by telephone, to explore participants’ experiences regarding chatbot use. Quantitative data were analyzed descriptively to summarize participant characteristics, chatbot use, and usability outcomes, while qualitative interview data were analyzed using thematic analysis. Results: A total of 56 participants were included in the final analysis (mean age 55.4 years, SD 13.7; female: n=39, 70%). Among them, 28 (50%) used the chatbot at least once. Chatbot users were younger than nonusers (51.1 vs 59.6 y; P =.02). Of the 25 users who agreed to log analysis, 347 inquiries were recorded; frequent topics included catheter care (126 observations), managing daily life (85 observations), symptoms (72 observations), and heparin use (55 observations). Among the 23 users who completed the usability survey, 20 (87%) reported that the chatbot was helpful for PICC-related issues. Qualitative interviews (N=56) identified 3 major benefits—information accessibility, effective guidance, and psychosocial support—while also revealing unmet needs related to conversational issues, user experience issues, and lack of personalization. Conclusions: A rule-based chatbot designed to support PICC self-management demonstrates potential to enhance information accessibility, provide practical guidance, and offer psychosocial support. However, limitations related to conversational flexibility, interface usability, and personalization highlight the need for future development incorporating large language models. Longitudinal and multisite studies are warranted to assess sustained user engagement and clinical outcomes.

10 October 2022 in JMIR Preprints
Verified
Preprint
Open access
MKMin Jeong Kim
Min Jeong Kim
HKHyo Jung Kim
Hyo Jung Kim
DKDanbee Kang
Danbee Kang
HAHee Kyung Ahn
Hee Kyung Ahn
SSSoo-Yong Shin
Soo-Yong Shin
Yeon Hee 박연희 ParkYeon Hee 박연희 Park
Yeon Hee 박연희 Park
BACKGROUND In recent decades, real-world evidence (RWE) in oncology has rapidly gained traction for its potential to answer clinical questions that cannot be directly addressed by randomized clinical trials. Integrating real-world data (RWD) into clinical research promises to contribute to more sustainable research designs, including extension, augmentation, enrichment, and pragmatic designs. Nevertheless, clinical research using RWD is still limited because of concerns regarding the shortage of best practices for extracting, harmonizing, and analyzing RWD. In particular, pragmatic screening methods to determine whether the content of a data source is sufficient to answer the research questions before conducting the research with RWD have not yet been established. OBJECTIVE We examined the PAR (Preliminary Attainability Assessment of Real-World Data) framework and assessed its utility in breast cancer brain metastasis (BCBM), which has an unmet medical need for data attainability screening at the preliminary step of observational studies that use RWD. METHODS The PAR framework was proposed to assess data attainability from a particular data source during the early research process. The PAR framework has four sequential stages, starting with clinical question clarification: (1) operational definition of variables, (2) data matching (structural/semantic), (3) data screening and extraction, and (4) data attainability diagramming. We identified 5 clinical questions to be used for PAR framework evaluation through interviews and validated them with a survey of breast cancer experts. We used the Samsung Medical Center Breast Cancer Registry, a hospital-based real-time registry implemented in March 2021, leveraging the institution’s anonymized and deidentified clinical data warehouse platform. The number of breast cancer patients in the registry was 45,129; it covered the period from June 1995 to December 2021. The registry consists of 24 base data marts that represent disease-specific breast cancer characteristics and care pathways. The outcomes included screening results of the clinical questions via the PAR framework and a procedural diagram of data attainability for each research question. RESULTS Data attainability was tested for study feasibility according to the PAR framework with 5 clinical questions for BCBM. We obtained data sets that were sufficient to conduct studies with 4 of 5 clinical questions. The research questions stratified into 3 types when we developed data fields for clearly defined research variables. In the first, only 1 question could be answered using direct data variables. In the second, the other 3 questions required surrogate definitions that combined data variables. In the third, the question turned out to be not feasible for conducting further analysis. CONCLUSIONS The adoption of the PAR framework was associated with more efficient preliminary clinical research using RWD from BCBM. Furthermore, this framework helped accelerate RWE generation through clinical research by enhancing transparency and reproducibility and lowering the entry barrier for clinical researchers.